News | May 29, 2022
Venus Remedies registers 9.22 % growth in annual sales for FY22
The company’s annual sales grew from Rs 548.12 crore in FY 2020-21 to Rs 598.65 crore this fiscal
The company’s annual sales grew from Rs 548.12 crore in FY 2020-21 to Rs 598.65 crore this fiscal
The acquisition is subject to customary closing conditions and necessary regulatory approvals. The financial terms of the transaction are confidential
Docosanol Cream, 10% (OTC) has an estimated market size of US$60 million for twelve months ending December 2021 according to IQVIA
Rodolfo brings with him a wealth of rich experience from commercial, marketing, and general management roles across several multinational companies
Company announced that it is accelerating its investment in its Leaps by Bayer impact investment unit with more than 1.3 billion euros funding until end of 2024
Saransh Chaudhary, President, Global Critical Care Division, Venus Remedies and CEO, Venus Medicine Research Centre In conversation with Thomas C Thottathil, Editor, www.indianpharmapost.com identified key areas that the company is focusing on in its Mission 2025
Haleon will have a portfolio of category-leading brands including Sensodyne, Voltaren, Panadol and Centrum
John served as General Manager for Catalent Pharma Solutions in St. Petersburg, Florida
EBITDA from Continuing Operations at Rs. 582 crore recorded a growth of 31 %.
Ascent Meditech has set benchmarks in introducing pain management products in India. The company has embarked on a new marketing campaign as it plans to enter new markets. Rajiv Mistry, Founder & Managing Director, Ascent Group shares his perspective with Thomas C Thottathil on the road ahead for the company and industry
Subscribe To Our Newsletter & Stay Updated
